Base de dados : MEDLINE
Pesquisa : C17.800.229 [Categoria DeCS]
Referências encontradas : 9628 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 963 ir para página                         

  1 / 9628 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29214786
[Au] Autor:Kim KY; Bae YS; Ji W; Shin D; Kim HS; Kim DS
[Ad] Endereço:Department of Pediatrics, Yonsei University College of Medicine, Severance Children's Hospital, Seoul, Korea.
[Ti] Título:ITPKC and SLC11A1 Gene Polymorphisms and Gene-Gene Interactions in Korean Patients with Kawasaki Disease.
[So] Source:Yonsei Med J;59(1):119-127, 2018 Jan.
[Is] ISSN:1976-2437
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Kawasaki disease (KD) is an acute systemic vasculitis. Both the etiology of KD and the erythema of Bacille Calmette-Guérin (BCG) injection sites observed in the disease are poorly understood. We investigated the association between KD and single nucleotide polymorphisms (SNPs) in two candidate genes: inositol 1,4,5-triphosphate 3-kinase (ITPKC), a well-studied KD-associated gene, and solute carrier 11a1 (SLC11A1), which is associated with the hypersensitive reaction to the BCG strain in Koreans. MATERIALS AND METHODS: Associations between KD and SNPs in two genes were evaluated. Potential associations between BCG injection site erythema and SNPs in two genes were also evaluated. Gene-gene interactions between ITPKC and SLC11A1 in KD and BCG injection site erythema were also analyzed. RESULTS: Three tagging SNPs in ITPKC and five tagging SNPs in SLC11A1 were genotyped in 299 KD patients and 210 control children. SNP rs28493229 in ITPKC was associated with KD and coronary artery complications. SNP rs77624405 in SLC11A1 was associated with KD. Comparisons of KD patients with and without BCG injection site erythema revealed that SNP rs17235409 in SLC11A1 was associated with erythema; no erythema-associated SNPs in ITPKC were identified. Interactions between ITPKC rs28493229_GG and SLC11A1 rs17235409_GA and between ITPKC rs10420685_GG and SLC11A1 rs17235409_AA were strongly associated with BCG injection site erythema. CONCLUSION: This study identified several important polymorphisms in the ITPKC and SLC11A1 genes in Koreans. The genetic variants identified in this study affected KD and erythema of BCG injection sites independently and through gene-gene interactions. Also, the effects of the polymorphisms were age-dependent.
[Mh] Termos MeSH primário: Grupo com Ancestrais do Continente Asiático/genética
Proteínas de Transporte de Cátions/genética
Epistasia Genética
Predisposição Genética para Doença
Síndrome de Linfonodos Mucocutâneos/genética
Fosfotransferases (Aceptor do Grupo Álcool)/genética
Polimorfismo de Nucleotídeo Único/genética
[Mh] Termos MeSH secundário: Vacina BCG/administração & dosagem
Estudos de Casos e Controles
Criança
Pré-Escolar
Eritema/complicações
Feminino
Estudos de Associação Genética
Seres Humanos
Lactente
Masculino
Taxa de Mutação
República da Coreia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (BCG Vaccine); 0 (Cation Transport Proteins); 0 (natural resistance-associated macrophage protein 1); EC 2.7.1.- (Phosphotransferases (Alcohol Group Acceptor)); EC 2.7.1.127 (Inositol 1,4,5-trisphosphate 3-kinase)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE
[do] DOI:10.3349/ymj.2018.59.1.119


  2 / 9628 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29452655
[Au] Autor:Amici JM; Chaussade V
[Ad] Endereço:Service de dermatologie, hôpital Saint-André, Bordeaux, France. Electronic address: jmamici@gmail.com.
[Ti] Título:[How to optimize scarring in dermatologic surgery?]
[Ti] Título:Optimisation de la cicatrisation en chirurgie dermatologique et gestions des aléas..
[So] Source:Ann Dermatol Venereol;143 Suppl 2:S20-S25, 2016 Dec.
[Is] ISSN:0151-9638
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:Scarring is the response elicited by the skin surface to injury and loss of tissue material. Wound healing takes place through a complex natural repair system consisting of vascular, inflammatory and proliferative phenomena, followed by a remodelling and cell apoptosis phase. This incredible repair system is inevitable, but sometimes unpredictable due to individual differences based on multiple factors. The scar is the objective criterion of a skin surgery, both for the patient and the dermsurgeon. It is therefore crucial to establish with the patient during the preoperative consultation, the size and positioning of the expected scar, taking into account the oncologic, anatomic and surgical constraints. Scars can ideally blend into normal skin, but may also give rise to various abnormalities. We can manage and prevent these abnormalities by mastering initial inflammation, that may induce hyperpigmentation and hypertrophy. Early massage using cortocosteroid topic or anti-inflammatory moisturizers may be effective. Random individual scarring may be minimized by a dynamic personalized accompanying scarring.
[Mh] Termos MeSH primário: Cicatriz/fisiopatologia
Procedimentos Cirúrgicos Dermatológicos/efeitos adversos
[Mh] Termos MeSH secundário: Corticosteroides/administração & dosagem
Anti-Inflamatórios/administração & dosagem
Cicatriz/prevenção & controle
Cicatriz Hipertrófica/fisiopatologia
Cicatriz Hipertrófica/prevenção & controle
Terapia Combinada
Eritema/fisiopatologia
Eritema/prevenção & controle
Hiperpigmentação/fisiopatologia
Hiperpigmentação/prevenção & controle
Queloide/fisiopatologia
Massagem
Educação de Pacientes como Assunto
Fatores de Risco
Pele/fisiopatologia
Transplante de Pele
Protetores Solares/administração & dosagem
Telangiectasia/fisiopatologia
Telangiectasia/prevenção & controle
Cicatrização/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Anti-Inflammatory Agents); 0 (Sunscreening Agents)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180218
[St] Status:MEDLINE


  3 / 9628 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29334624
[Au] Autor:Guzikowski J; Krzyscin J; Czerwinska A; Raszewska W
[Ad] Endereço:Institute of Geophysics, Polish Academy of Sciences, Warsaw, Poland.
[Ti] Título:Adequate vitamin D skin synthesis versus erythema risk in the Northern Hemisphere midlatitudes.
[So] Source:J Photochem Photobiol B;179:54-65, 2018 Feb.
[Is] ISSN:1873-2682
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Health-optimum-exposure index (HOEI) is proposed to assess if the prescribed amount of vitamin D (target value) could be synthesized in the human skin without erythema appearance. It is defined as the ratio between the vitamin D quantity received during the maximum allowed outdoor exposure without erythema risk and the target value. Sunbathing is safe for HOEI>1 and 1/HOEI represents a part of minimal erythema dose (MED) necessary to obtain the target value. We examine the following targets: a vitamin D quantity equivalent to 1000 IU vitamin D taken orally, and an optimal vitamin D quantity defined by Krzyscin et al. (2016). The biologically weighted (previtamin D and erythemal) doses from the Northern Hemisphere midlatitudinal stations are analyzed to find HOEI dependence on personal and meteorological factors. HOEI depends mostly on the exposed skin area, person's age, and sun elevation at noon but not on the Fitzpatrick skin phototype. We found that only young adults (<21 yr) could safely obtain vitamin D quantity, which is equivalent to 1000 IU taken orally, almost throughout the whole year. Duration of such exposures appears <1 h only in the warm subperiods of the year (April-September) for a person with minimal erythema dose of 330 J m . Exposing larger part of the body (~30%) enables the oldest persons (>59 yr) to reach 1000 IU target during warm days in spring and summer. The optimal daily vitamin D quantity could only be synthesized only by young adults for about 40-60% of days in the May-August period if they expose at least 1/3 part of their body surface area. Vitamin D supplementation seems to be necessary over the whole year for the oldest persons with daily dosage of ~2000 IU but reduced to ~1000 IU in summer for sunseekers exposing significant part of the body.
[Mh] Termos MeSH primário: Colecalciferol/biossíntese
Eritema/etiologia
Pele/efeitos da radiação
Luz Solar
[Mh] Termos MeSH secundário: Colecalciferol/análise
Seres Humanos
Meia-Idade
Fenótipo
Estações do Ano
Pele/metabolismo
Temperatura Ambiente
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
1C6V77QF41 (Cholecalciferol)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180116
[St] Status:MEDLINE


  4 / 9628 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27779320
[Au] Autor:Wernham AG; Fremlin GA; Orpin SD; Salim A
[Ad] Endereço:Department of Dermatology, Heart of England NHS Foundation Trust, Solihull Hospital, Birmingham, UK.
[Ti] Título:Physician, beware! The deckchair sign can be seen in dermatomyositis.
[So] Source:Clin Exp Dermatol;41(8):919-920, 2016 Dec.
[Is] ISSN:1365-2230
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Dermatomiosite/patologia
[Mh] Termos MeSH secundário: Idoso
Eritema/patologia
Seres Humanos
Masculino
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180112
[Lr] Data última revisão:
180112
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1111/ced.12948


  5 / 9628 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28837365
[Au] Autor:Patel NU; Shukla S; Zaki J; Feldman SR
[Ad] Endereço:a Center for Dermatology Research, Department of Dermatology , Wake Forest School of Medicine , Winston-Salem , NC , USA.
[Ti] Título:Oxymetazoline hydrochloride cream for facial erythema associated with rosacea.
[So] Source:Expert Rev Clin Pharmacol;10(10):1049-1054, 2017 Oct.
[Is] ISSN:1751-2441
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Rosacea is a chronic skin condition characterized by transient and persistent erythema of the central face. The symptom of persistent erythema can be particularly frustrating for both patients and physicians as it is difficult to treat. Areas covered: Current treatment options for the treatment of rosacea include metronidazole, azelaic acid, sodium sulfacetamide-sulfur, and brimonidine. Until recently, brimonidine gel was the only option approved specifically for the treatment of facial erythema. However, oxymetazoline hydrochloride 1% cream is a newly FDA approved topical medication for adult rosacea patients. A primarily alpha-1a agonist, oxymetazoline hydrochloride (HCl) is thought to diminish erythema through vasoconstriction. Our paper seeks to evaluate evidence for topical oxymetazoline HCl with respect to its efficacy and safety for its approved indication of treating the persistent erythema associated with rosacea. Expert commentary: While assessment of available clinical trial data indicates that the medication is as effective as other available treatment for controlling rosacea-associated erythema with minimal risk of adverse effects, studies of long-term duration and direct comparison will be necessary to establish its place in treatment guidelines and clinical practice. As further evidence becomes available, the real-world clinical potential of topical oxymetazoline cream will become clearer.
[Mh] Termos MeSH primário: Eritema/tratamento farmacológico
Oximetazolina/administração & dosagem
Rosácea/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Cutânea
Agonistas alfa-Adrenérgicos/administração & dosagem
Agonistas alfa-Adrenérgicos/efeitos adversos
Agonistas alfa-Adrenérgicos/farmacologia
Fármacos Dermatológicos/administração & dosagem
Fármacos Dermatológicos/efeitos adversos
Fármacos Dermatológicos/farmacologia
Eritema/etiologia
Eritema/patologia
Seres Humanos
Oximetazolina/efeitos adversos
Oximetazolina/farmacologia
Rosácea/patologia
Creme para a Pele
Vasoconstrição/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Adrenergic alpha-Agonists); 0 (Dermatologic Agents); 8VLN5B44ZY (Oxymetazoline)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170825
[St] Status:MEDLINE
[do] DOI:10.1080/17512433.2017.1370370


  6 / 9628 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28825957
[Au] Autor:Kohavi L; Sprecher E; Zur E; Artzi O
[Ad] Endereço:*Department of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; †Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; ‡LogiPharm Compounding Pharmacy, Tel-Mond, Israel.
[Ti] Título:The Effect of Tranilast 8% Liposomal Gel Versus Placebo on Post-Cesarean Surgical Scars: A Prospective Double-Blind Split-Scar Study.
[So] Source:Dermatol Surg;43(9):1157-1163, 2017 Sep.
[Is] ISSN:1524-4725
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Tranilast (N-[3, 4-dimethoxycinnamoyl] anthranilic acid), an antiallergic drug, has been shown to attenuate scar formation possibly through inhibition of transforming growth factor beta 1 activity and consequent suppression of collagen synthesis in fibroblasts. OBJECTIVE: The authors aimed at evaluating the efficacy and safety of tranilast 8% gel in improving the appearance and symptoms of new post-cesarean section surgical wounds. METHODS: In this prospective double-blind split-scar study, the authors treated each half scar of 26 women with either tranilast 8% liposomal gel or tranilast-free liposomal gel (placebo). Treatment was applied twice daily for 3 months. Twenty women completed the trial. Scar halves were evaluated by 2 investigators and by the patients 9 months after the last application using the Patient and Observer Scar Assessment Scale (POSAS). The participants also rated overall satisfaction and recorded side effects of the treatment. RESULTS: The mean POSAS scores at 9 months post-treatment were significantly lower for tranilast-treated half scars compared with placebo-treated half scars (p < .001). The women were significantly more satisfied with the tranilast-treated half-scar appearance (p = .002). Three participants reported itching and erythema on the tranilast-treated side. CONCLUSION: Topical tranilast 8% gel provided significantly better postcaesarian section scar cosmesis and user satisfaction compared with placebo.
[Mh] Termos MeSH primário: Cesárea/efeitos adversos
Cicatriz/tratamento farmacológico
Fármacos Dermatológicos/uso terapêutico
Complicações Pós-Operatórias/tratamento farmacológico
Fator de Crescimento Transformador beta1/antagonistas & inibidores
ortoaminobenzoatos/uso terapêutico
[Mh] Termos MeSH secundário: Administração Cutânea
Adulto
Fármacos Dermatológicos/administração & dosagem
Fármacos Dermatológicos/efeitos adversos
Método Duplo-Cego
Eritema/induzido quimicamente
Feminino
Géis
Seres Humanos
Meia-Idade
Satisfação do Paciente
Estudos Prospectivos
Prurido/induzido quimicamente
Resultado do Tratamento
Adulto Jovem
ortoaminobenzoatos/administração & dosagem
ortoaminobenzoatos/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Dermatologic Agents); 0 (Gels); 0 (Transforming Growth Factor beta1); 0 (ortho-Aminobenzoates); HVF50SMY6E (tranilast)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170831
[Lr] Data última revisão:
170831
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170822
[St] Status:MEDLINE
[do] DOI:10.1097/DSS.0000000000001140


  7 / 9628 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28783775
[Au] Autor:O'Brien JM; Baum JD
[Ad] Endereço:Division of Maternal Fetal Medicine, Penn State College of Medicine, Hershey, PA, USA. Email: obrija02@gmail.com.
[Ti] Título:Low-grade fever, erythematous rash in pregnant woman · Dx?
[So] Source:J Fam Pract;66(8):E9-E10, 2017 Aug.
[Is] ISSN:1533-7294
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A 31-year-old woman presented to her obstetrician's office at 16 weeks' gestation with a 2-day history of low-grade fever and an erythematous rash measuring 1 x 4 cm on her right groin. She had a medical history of a penicillin allergy (urticarial) and her outdoor activities included gardening and picnicking. What's your diagnosis?
[Mh] Termos MeSH primário: Eritema/etiologia
Febre/etiologia
Doença de Lyme/diagnóstico
Complicações Infecciosas na Gravidez/diagnóstico
[Mh] Termos MeSH secundário: Antibacterianos/uso terapêutico
Diagnóstico Diferencial
Feminino
Seres Humanos
Doença de Lyme/complicações
Doença de Lyme/tratamento farmacológico
Gravidez
Complicações Infecciosas na Gravidez/tratamento farmacológico
[Pt] Tipo de publicação:CASE REPORTS
[Nm] Nome de substância:
0 (Anti-Bacterial Agents)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170904
[Lr] Data última revisão:
170904
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170808
[St] Status:MEDLINE


  8 / 9628 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28697472
[Au] Autor:Che DN; Xie GH; Cho BO; Shin JY; Kang HJ; Jang SI
[Ad] Endereço:Department of Health Care & Science, Jeonju University, Jeonju 55069, Republic of Korea.
[Ti] Título:Protective effects of grape stem extract against UVB-induced damage in C57BL mice skin.
[So] Source:J Photochem Photobiol B;173:551-559, 2017 Aug.
[Is] ISSN:1873-2682
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Humans have become exposed to another form of a trait which is ultraviolet B (UVB) radiation reaching the earth's surface. This has become a major source of oxidative stress that ultimately leads to inflammation, DNA damage, photoaging and pigmentation disorders etc. Although several studies have shown the photo-protective role of different grape parts like the fruits and seeds, little or no data demonstrating the in vivo photo-protective role of grape stem, which is the most discarded part of the grape are available. We evaluated the protective influence of grape stem extract against UVB-induced oxidative damage in C57BL mice characterized by epidermal hyperplasia, pigmentation, collagen degradation and inflammation. Grape stem extract was administered topically 1week before UVB irradiation (120mJ/cm ) and continued until the termination of the experiment. A group of non-irradiated mice and a group of irradiated mice topically administered with propylene were used as a negative and positive control. Epidermal thickness, pigmentation, erythema, mast cell and neutrophil infiltration, collagen degradation and COX-2, Nrf2, and HO-1 expressions were evaluated. Grape stem extract markedly recovered skin damage induced by the UVB radiation through the prevention of epidermal hyperplasia, pigmentation, erythema, mast cell and neutrophil infiltrations, collagen degradation and COX-2, Nrf2, and HO-1 expressions. Our study demonstrated for the first time in C57BL mice that grape stem extract reduces UVB-induced oxidative damage and hence can play a protective role in skin photo-damage.
[Mh] Termos MeSH primário: Extrato de Sementes de Uva/farmacologia
Substâncias Protetoras/farmacologia
Pele/efeitos dos fármacos
Raios Ultravioleta
[Mh] Termos MeSH secundário: Animais
Cromatografia Líquida de Alta Pressão
Colágeno/genética
Colágeno/metabolismo
Ciclo-Oxigenase 2/genética
Ciclo-Oxigenase 2/metabolismo
Eritema/patologia
Expressão Gênica/efeitos dos fármacos
Expressão Gênica/efeitos da radiação
Glutationa/análise
Heme Oxigenase-1/genética
Heme Oxigenase-1/metabolismo
Masculino
Malondialdeído/análise
Proteínas de Membrana/genética
Proteínas de Membrana/metabolismo
Camundongos
Camundongos Endogâmicos C57BL
Extratos Vegetais/análise
Extratos Vegetais/química
Pele/efeitos da radiação
Pigmentação da Pele/efeitos dos fármacos
Pigmentação da Pele/efeitos da radiação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Grape Seed Extract); 0 (Membrane Proteins); 0 (Plant Extracts); 0 (Protective Agents); 4Y8F71G49Q (Malondialdehyde); 9007-34-5 (Collagen); EC 1.14.14.18 (Heme Oxygenase-1); EC 1.14.14.18 (Hmox1 protein, mouse); EC 1.14.99.- (Ptgs2 protein, mouse); EC 1.14.99.1 (Cyclooxygenase 2); GAN16C9B8O (Glutathione)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170712
[St] Status:MEDLINE


  9 / 9628 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28677489
[Au] Autor:Birner B; Glauser T; Balmer F; Escher R; Klein M
[Ad] Endereço:1 Medizinische Klinik, Regionalspital Emmental Standort Burgdorf, Burgdorf.
[Ti] Título:Wie lautet Ihre Diagnose?.
[So] Source:Praxis (Bern 1994);106(14):755-756, 2017 Jul.
[Is] ISSN:1661-8157
[Cp] País de publicação:Switzerland
[La] Idioma:ger
[Mh] Termos MeSH primário: Eritema/etiologia
Dermatoses da Perna/etiologia
Perna (Membro)/irrigação sanguínea
Púrpura/diagnóstico
Púrpura/etiologia
Vasculite/diagnóstico
Vasculite/etiologia
[Mh] Termos MeSH secundário: Idoso
Diagnóstico Diferencial
Feminino
Seres Humanos
Esforço Físico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170828
[Lr] Data última revisão:
170828
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170706
[St] Status:MEDLINE
[do] DOI:10.1024/1661-8157/a002724


  10 / 9628 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28624524
[Au] Autor:Ball JF; Sheena Y; Tarek Saleh DM; Forouhi P; Benyon SL; Irwin MS; Malata CM
[Ad] Endereço:Department of Plastic and Reconstructive Surgery, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, UK.
[Ti] Título:A direct comparison of porcine (Strattice™) and bovine (Surgimend™) acellular dermal matrices in implant-based immediate breast reconstruction.
[So] Source:J Plast Reconstr Aesthet Surg;70(8):1076-1082, 2017 Aug.
[Is] ISSN:1878-0539
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Acellular dermal matrix (ADM) assisted implant-based breast reconstruction (IBBR) has grown in popularity over traditional submuscular techniques. Numerous human, bovine or porcine derived ADMs are available with the type used varying considerably worldwide. Yet, comparative evidence for the efficacy of different ADMs particularly xenogenic is limited. This study directly compares early outcomes of porcine (Strattice™) and bovine (Surgimend™) ADMs in IBBR. METHOD: Retrospective study of sequential experience of immediate IBBR using Strattice or Surgimend ADM. Data was collected for patients undergoing ADM assisted IBBR after prophylactic or therapeutic mastectomy in Cambridge (October 2011-March 2016). Patient demographics, adjuvant and neoadjuvant therapies, operative details, postoperative management and outcomes were analysed. KEY RESULTS: Total of 81 patients underwent IBBR with ADM; 38 bilateral and 43 unilateral (n = 119 breasts). Strattice was used in 30 breasts (25%) and Surgimend in 89 (75%). Analysis of patient specific variables showed statistical significance only for higher mastectomy weight in the Strattice group (367.1 ± 159.3 g versus 296.3 ± 133.4 g; P = 0.0379). Strattice was associated with higher rates of skin erythema post-operatively (16.7% versus 4.5%; P = 0.044). Analysed per woman or per breast, there was no statistically significant difference in rates of haematoma, infection, wound dehiscence, skin necrosis or seroma, although there was a trend towards more complications with Strattice. CONCLUSION: This study found significantly higher rates of skin erythema and a trend towards higher complication rates with Strattice in IBBR. Randomised controlled trials comparing different ADM outcomes are needed to inform best practice.
[Mh] Termos MeSH primário: Derme Acelular
Neoplasias da Mama/terapia
Mama/patologia
Colágeno/uso terapêutico
Mamoplastia
Pele/patologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Animais
Implantes de Mama
Bovinos
Colágeno/efeitos adversos
Eritema/etiologia
Feminino
Hematoma/etiologia
Seres Humanos
Mamoplastia/efeitos adversos
Mastectomia
Meia-Idade
Necrose
Tamanho do Órgão
Reoperação
Estudos Retrospectivos
Seroma/etiologia
Deiscência da Ferida Operatória/etiologia
Infecção da Ferida Cirúrgica/etiologia
Suínos
Fatores de Tempo
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Surgimend); 0 (strattice); 9007-34-5 (Collagen)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170619
[St] Status:MEDLINE



página 1 de 963 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde